You are here

FDA Grants Priority Review to Hepatitis C Combo Drug

Approval decision expected in June 2016

The FDA has granted priority review to the new drug application (NDA) for an investigational once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi (Gilead Sciences) in December 2013, and velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1–6 hepatitis C virus (HCV) infection.

Gilead Sciences filed the NDA for SOF/VEL in October 2015, and the FDA set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 28, 2016. The agency also assigned SOF/VEL a breakthrough therapy designation, which is granted to investigational medications that may offer major advances in treatment over existing options.

The NDA for SOF/VEL was supported by data from four phase III clinical trials. In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, a total of 1,035 patients with genotype 1–6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21% had compensated cirrhosis and 28% had failed prior treatments. The ASTRAL-4 study randomly assigned 267 patients with decompensated cirrhosis (Child-Pugh class B) to receive 12 weeks of SOF/VEL with or without ribavirin (RBV), or 24 weeks of SOF/VEL. In all of these studies, the primary endpoint was undetectable HCV for 12 or more weeks after the end of treatment (SVR12).

Of the 1,035 patients treated with SOF/VEL for 12 weeks in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,015 (98%) achieved the primary efficacy endpoint of SVR12. Of the 20 patients who did not achieve SVR12, 13 patients (1.3%) experienced virologic failure and seven did not complete an SVR12 visit (e.g., lost to follow-up). Twelve of the 13 patients with virologic failure relapsed (two genotype 1 HCV-infected patients and 10 genotype 3 HCV-infected patients). One patient had documented reinfection. No patients with genotype 2, 4, 5, or 6 HCV infection experienced virologic failure.

Patients treated with SOF/VEL for 12 weeks in these three studies had similar adverse events compared with placebo-treated patients in ASTRAL-1. Two patients (0.2%) treated with SOF/VEL for 12 weeks, one each in ASTRAL-1 and ASTRAL-2, discontinued treatment because of adverse events. The most common adverse events were headache, fatigue, and nausea.

In ASTRAL-4, patients with Child-Pugh class B cirrhosis receiving SOF/VEL plus RBV achieved higher SVR12 rates compared with patients receiving SOF/VEL alone for 12 or 24 weeks. Among genotype 1 and 3 patients treated with SOF/VEL plus RBV for 12 weeks, the SVR12 rates were 96% and 85%, respectively.

The most common adverse events across all arms of the ASTRAL-4 trial were fatigue, nausea, and headache. Anemia, a common adverse effect associated with RBV, was reported in 31% of patients in the SOF/VEL plus RBV arm, and in 4% and 3% of patients treated with SOF/VEL for 12 or 24 weeks, respectively. Treatment-emergent serious adverse events occurred in 18% of patients, and nine patients died. Most of the serious adverse events and deaths were associated with advanced liver disease.

The SOF/VEL fixed-dose combination is an investigational product, and its safety and efficacy have not been established.

Sources: Gilead Sciences; January 4, 2016; and Gilead Sciences; September 21, 2015.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs